-
The growth potential of this drug market is huge, and the scale has exceeded 100 billion yuan.
Time of Update: 2022-04-30
For example, Yuekang Pharmaceutical told investors on the interactive platform on February 21 that the company's peptide drugs are currently in the preclinical research stage in China.
-
Four medicines including Jigucao Capsules were selected into the list of newly added National Medical Insurance Catalogue for online purchase
Time of Update: 2022-04-30
On March 9, 2022, the Shanghai Pharmaceutical Centralized Bidding and Procurement Office issued a notice on the announcement of some new drugs on the National Medical Insurance Catalogue for online procurement .
-
What are the prospects for each of the three major segments of biopharmaceuticals?
Time of Update: 2022-04-30
According to the "2020 China Gene Engineering Drug Project Business Plan" released by the Xinsijie Industry Research Center, in 2019, the global market size has exceeded 2 trillion yuan, and China's genetic engineering drug market share in the global market is relatively Small, the scale in the same year was only about 280 billion yuan, and the future market growth potential is huge .
-
A large number of pharmaceutical companies are competing for the breast cancer drug market, and the price war is imminent!
Time of Update: 2022-04-30
On March 6, the multinational pharmaceutical company Eli Lilly announced that its CDK4/6 inhibitor Abeccil (trade name: Weizhe) has been approved for early breast cancer indications in China.
-
At the current time, optimistic about the two directions of the traditional Chinese medicine sector and pharmaceutical equipment
Time of Update: 2022-04-30
For example, Chutian Technology said in a recent survey that the company has been deploying import substitution in the high-end market of vaccine products four years ago, and the product performance and quality have been able to meet the needs of high-end customers .
-
Domestic pharmaceutical machines usher in a development window period!
Time of Update: 2022-04-30
For example, it has been reported recently that the R&D and industrialization project of disposable equipment/consumables with a total investment of 200 million yuan for Bailinke pharmaceutical machine has been completed and put into production, and the average annual R&D investment will reach 10%.
-
Antengene Announces Approval of Phase I Clinical Trial Application of ATG-101 in China
Time of Update: 2022-04-30
SHANGHAI, CHINA & HONG KONG, March 10, 2022 /PRNewswire/ -- A leading commercial-stage innovative biopharmaceutical company dedicated to developing, manufacturing and marketing first-in-class and/or best-in-class hematologic and solid tumor therapies – Antengene Pharma Co.
-
Sihuan, Junshi, Hengrui and other pharmaceutical companies have been approved for clinical trials
Time of Update: 2022-04-30
Sihuan Pharmaceutical's innovative drug HER2 dual anti-XZP-KM257 was approved for clinical trials Sihuan Pharmaceutical recently announced that a class 1 innovative drug XZP-KM257 (recombinant anti-HER2 domain II and A clinical trial application for IV Bispecific Antibody Injection) (“KM257”) for the treatment of advanced solid tumors with medium and high expression of HER2+ has been successfully approved by the China National Medical Products Administration .
-
Antengene's PD-L1/4-1BB dual antibody ATG-101 for injection was approved for clinical use
Time of Update: 2022-04-30
Recently, the official website of the Center for Drug Evaluation (CDE) of the China National Medical Products Administration announced that ATG-101 for injection declared by Antengene has been approved for clinical use, and the proposed indications are advanced/metastatic solid tumors and mature B-cell non-Hodge.
-
First-line treatment of non-small cell lung cancer mRNA vaccine/PD-1 antibody combination is about to enter the clinic
Time of Update: 2022-04-30
On March 9, BioNTech announced that it has expanded its strategic R&D cooperation with Regeneron, and will jointly promote the clinical trial of BioNTech's candidate cancer vaccine BNT116 in combination with the PD-1 inhibitor Libtayo (cemiplimab) for the treatment of advanced stage Non-small cell lung cancer (NSCLC) patients .
-
Otsuka Pharmaceutical's anti-APRIL monoclonal antibody VIS649 applied for clinical application in China
Time of Update: 2022-04-30
On March 8, the official website of the Center for Drug Evaluation (CDE) of the China National Medical Products Administration announced that Otsuka Pharmaceutical applied for the clinical trial application of VIS649 and was accepted .
-
Junshi Engineering, a wholly-owned subsidiary of Junshi Bio, passed the drug GMP compliance inspection
Time of Update: 2022-04-30
Toripalimab injection produced by Junshi Engineering's Shanghai Lingang Production Base has passed the compliance inspection of the drug production quality management standard organized by the Shanghai Municipal Food and Drug Administration .
-
Buy, buy, buy, "smash" out the future?
Time of Update: 2022-04-30
According to the announcement at the time, the capital increase in Ougen Gene is in line with the company's development strategy, which is conducive to optimizing the company's industrial layout, expanding its business scale, making full use of local talent and location and other resource advantages, reducing R&D costs and production costs, and improving the company's economic benefits and comprehensive strength.
-
Tide Pharma's first-class innovative drug for pneumoconiosis was approved for clinical use
Time of Update: 2022-04-30
Ted Pharmaceuticals revealed that TDI01 has completed Phase I clinical trials in the United States with good safety, and is currently conducting bridging trials in China .
Strengthening technological innovation and R&D is the most important responsibility of pharmaceutical companies to contribute to society.
-
The launch of innovative medical devices in my country has accelerated, and the number of approved medical devices has reached 148
Time of Update: 2022-04-30
It is reported that from January to February 2022, the State Food and Drug Administration has approved 13 innovative medical device products for the market, exceeding the number from 2014 to 2017 .
-
Euho Pharma's global multicenter Phase I clinical study of YH002 (OX40 antibody) combined with YH001 (CTLA-4 antibody) completed the first patient dosing
Time of Update: 2022-04-30
BEIJING, March 8, 2022 /PRNewswire/ -- Euho Pharma, a wholly-owned subsidiary of Biositu, today announced an international multi-center ( MRCT) Phase I clinical study (No.
In preclinical animal models, we found that YH002 and CTLA-4 inhibitor (YH001 ) combined with better antitumor activity than single drugs .
-
Transwin Group Presents Preliminary Data on Safety, Tolerability and Antitumor Activity of TST001 Monotherapy in China Phase I Clinical Trial at the 2022 International Gastric Cancer Congress
Time of Update: 2022-04-30
SUZHOU, March 10, 2022 /PRNewswire/ -- Chuangsheng Group, a clinical-stage biopharmaceutical company with the ability to integrate the whole process of biopharmaceutical discovery, R&D, process development and production, announced that at the 2022 International Gastric Cancer Congress (IGCC) ) in the form of a poster to show the safety, tolerability and preliminary efficacy data of TST001 monotherapy in the Phase I clinical trial in China and its antitumor activity against gastric and pancreatic cancer .
-
Pharmaceutical companies are scrambling to deploy CDK4/6 inhibitors, and market competition is becoming more intense
Time of Update: 2022-04-30
A few days ago, Eli Lilly announced in Shanghai that its CDK4/6 inhibitor Abeccil (trade name: Weizhe) was officially launched in China for early breast cancer indications .
-
In 2022, a large number of domestic innovative drugs will gradually usher in the harvest period!
Time of Update: 2022-04-30
Up to now, the number of innovative drugs approved for marketing by Hengrui Medicine has increased to 10 .
With the advancement of the research and development of innovative drugs in China, Fosun Pharma's innovative products have gradually entered the harvest period.
-
The pharmaceutical outsourcing sector went up on March 10. What will happen next?
Time of Update: 2022-04-29
The industry believes that the Wuxi base has passed the PAI of the first EMA formulation project, which means that WuXi AppTec's layout in the global CXO market has reached a new level .
